Written and maintained by CASRAI Editorial Board
Published
On this page
Annex 13: Investigational Medicinal Products and the CTR
Annex 13 was the traditional regulatory framework for the Good Manufacturing Practice (GMP) of Investigational Medicinal Products (IMPs) in the European Union. It has been replaced by the Clinical Trials Regulation (CTR) (EU) No 536/2014, which integrated GMP requirements for IMPs into a unified framework. This guide outlines the regulatory status and current compliance landscape for IMPs as of November 17, 2026.
What it is and who runs it
Annex 13 was formerly a part of EudraLex Volume 4, the primary set of guidelines for GMP in the EU. It provided specific instructions for the manufacturing and labeling of IMPs for clinical trials. Under the new Clinical Trials Regulation (EU) No 536/2014, the core principles of GMP for IMPs are established in the Regulation itself and in Commission Delegated Regulation (EU) 2017/1569. The regulatory framework is overseen by the national competent authorities in each EU Member State.
Eligibility
The Clinical Trials Regulation (CTR) applies to all clinical trials conducted in the European Union, regardless of where the sponsor is located, if the trial is conducted within an EU Member State. IMPs used in these trials must adhere to GMP standards.
What it requires
Compliance requires a robust Quality Management System (QMS) specifically tailored to the manufacturing of IMPs. Key requirements include:
- Personnel: Qualified and experienced staff responsible for manufacturing and quality control.
- Facilities: Adequate premises and equipment to ensure the quality, safety, and efficacy of the IMPs, with rigorous controls to prevent cross-contamination.
- Documentation: Maintenance of comprehensive records, including the Investigational Medicinal Product Dossier (IMPD) or equivalent, which details the manufacturing process, quality control, and testing.
- Labeling: IMPs must be clearly labeled according to the requirements set out in the CTR to ensure traceability, blinding where applicable, and safety information.
Application or compliance steps
- Establish a QMS that addresses the specific needs of IMP manufacturing.
- Compile all necessary data on the IMP’s manufacturing process, quality control tests, and safety data.
- Ensure the manufacturing facility holds the required authorization for the production of IMPs.
- Perform batch release testing and ensure adherence to specifications.
- Maintain records for audit and inspection by national competent authorities.
Typical timeline phases
- Pre-Trial Manufacturing: Development of the manufacturing process, quality control tests, and preparation of the IMP Dossier.
- Clinical Trial Supply: Production and packaging of the IMPs according to trial requirements.
- Batch Release: Quality assurance review and certification of each batch before its release for clinical use.
- Trial Conduct: Ongoing compliance with GMP requirements throughout the duration of the clinical trial.
Common mistakes
- Documentation Failures: Incomplete or inaccurate batch records or documentation in the IMP Dossier.
- Labeling Errors: Incorrect or non-compliant labeling of IMPs, which can compromise trial blinding or subject safety.
- Traceability Issues: Failure to adequately track IMPs throughout the supply chain.
- Inadequate QMS: A system that does not specifically address the unique requirements of IMP manufacturing.
Related programs
For more information on the regulatory framework, see the dataset below, which summarizes related EU clinical trial programs.
Frequently asked questions
Is Annex 13 still in use?
No. Annex 13 has been replaced by the Clinical Trials Regulation (EU) No 536/2014, which now provides the regulatory framework for IMPs in the EU.
How do I ensure compliance for my IMP?
Compliance requires following the requirements of the CTR, which includes maintaining a robust QMS, preparing an IMP Dossier, ensuring your manufacturing facility is authorized, and adhering to GMP standards throughout the manufacturing process.
Sources
- Regulation (EU) No 536/2014 of the European Parliament and of the Council (Clinical Trials Regulation)
- Commission Delegated Regulation (EU) 2017/1569
- European Commission, EudraLex Volume 4: GMP for Investigational Medicinal Products
- Information as described on the European Commission website, checked on November 17, 2026.
Data: Related EU Clinical Trial Programs and Regulations
This table compares key regulatory frameworks and guidelines governing clinical trials and Investigational Medicinal Products (IMPs) in the European Union, compiled from EU legal documents.
| Program/Regulation | Description | Relationship to IMPs |
|---|---|---|
| Regulation (EU) 536/2014 (CTR) | Clinical Trials Regulation | Replaces Annex 13 and governs trial conduct and IMP requirements. |
| EudraLex Volume 4 | GMP Guidelines | Provides detailed guidance for GMP compliance in the EU. |
| Good Clinical Practice (GCP) | Standards for trial conduct | Ensures the rights, safety, and well-being of trial subjects are protected. |
Sources
- Regulation (EU) No 536/2014 (accessed 2026-11-17)
- EudraLex Volume 4 (accessed 2026-11-17)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







